Activity ID
14396Expires
September 3, 2028Format Type
Journal-basedCME Credit
1Fee
$30CME Provider: JAMA Surgery
Description of CME Course
Importance Use of percutaneous cholecystostomy (PC) has increased over the past 20 years without consensus regarding indications and management.
Objective To identify indicators for PC, clarify the management of a PC tube (PCT), and suggest the timing of further interventions.
Evidence Review A systematic review was conducted to identify studies examining PC. Five databases were selected and searched from inception to December 31, 2024: PubMed, Embase, Cochrane, ICTRP, and ClinicalTrials.gov. Inclusion criteria were prior systematic reviews and meta-analyses published within the last 5 years, randomized clinical trials, prospective cohort studies, retrospective cohorts, cross-sectional studies, and case-control studies with multivariate analyses.
Findings Of 3774 publications identified, 69 studies met the inclusion criteria. There were 5 randomized clinical trials, 2 prospective cohort analyses, 40 retrospective cohort analyses, 1 case-control study, 12 cross-sectional studies, 3 systematic reviews, and 6 meta-analyses. PC was outperformed by cholecystectomy and offered no apparent benefit compared to antibiotic-only management (AOM) except among patients with concomitant sepsis. Interval cholecystectomy (IC) following PC was associated with better outcomes compared to a definitive PC. Factors associated with failure to undergo IC include congestive heart failure (CHF) and chronic liver disease (CLD). IC within 8 weeks and beyond 13 weeks after PC was associated with increased complications. Removal of PC before IC was associated with reduced complications but an increase in the likelihood of undergoing emergency IC. A PCT clamp trial was a better test than tube cholangiogram for PCT removal.
Conclusion and Relevance PC should only be considered among poor surgical candidates unable to undergo immediate cholecystectomy. Indications for PC include cholecystitis sepsis or AOM failure. PC should be approached as a bridging therapy to IC with careful consideration among patients with CHF and CLD. PC removal before IC should be guided by a successful clamping trial to reduce complications and interim recurrence. IC should be performed 8 to 13 weeks after PC.
Disclaimers
1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Allergy and Immunology
Anesthesiology
Colon and Rectal Surgery
Family Medicine
Medical Genetics and Genomics
Nuclear Medicine
Ophthalmology
Pathology
Physical Medicine and Rehabilitation
Plastic Surgery
Preventive Medicine
Psychiatry and Neurology
Radiology
Thoracic Surgery
Urology
Commercial Support?
NoNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
To identify the key insights or developments described in this article
Keywords
Gastroenterology and Hepatology, Hepatobiliary Disease, Hepatobiliary Surgery, Surgery, Critical Care Medicine
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
DOI
10.1001/jamasurg.2025.3260